Signs to Watch: Recognizing Tardive Dyskinesia from Reglan Use

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Education to Targeted Risk Awareness

If you or a loved one has been taking Reglan and notice involuntary movements—like lip smacking, tongue thrusting, or facial grimacing—these could be early signs of tardive dyskinesia, a potentially irreversible movement disorder. Decades of pharmacovigilance have established a clear link between long-term metoclopramide use and this condition, underscoring the importance of symptom recognition. This page outlines the key symptoms to watch for and the FDA's prescribing information for Illinois patients.

Reglan and Tardive Dyskinesia: Medical Evidence and FDA Warnings

Reglan (metoclopramide) is a prescription medication approved for short-term use in adults with symptomatic gastroesophageal reflux disease (GERD) and diabetic gastroparesis. The FDA-approved labeling explicitly states that Reglan is indicated for treatment of GERD for 4 to 12 weeks and for relief of symptoms in acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling also notes that Reglan has not been shown to be safe and effective for GERD treatment beyond 12 weeks and is not recommended for pediatric patients due to the risk of tardive dyskinesia (TD) and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is a potentially irreversible movement disorder characterized by involuntary, repetitive movements of the face, tongue, trunk, and extremities. The FDA boxed warning for Reglan states that metoclopramide can cause TD, and the risk increases with longer treatment duration and higher cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The warning further notes that Reglan is contraindicated in patients with a history of TD, and that the drug should be used for the shortest duration necessary, with periodic reassessment of continued need (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with diabetic gastroparesis, the labeling advises avoiding total treatment duration longer than 12 weeks, and if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway linking Reglan to TD involves metoclopramide's action as a dopamine receptor antagonist in the central nervous system. Chronic blockade of dopamine D2 receptors in the basal ganglia is believed to lead to upregulation of dopamine receptors and subsequent supersensitivity, which can manifest as the involuntary movements characteristic of TD. The FDA warnings and precautions section notes that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis by masking the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This masking effect is clinically significant because it can allow TD to progress unrecognized until movements become more pronounced or irreversible.

Legal Context: Statute of Limitations for Reglan Claims in Illinois

From a risk perspective, the adequacy of warnings regarding Reglan and TD is a central consideration. The FDA boxed warning is prominently displayed on the prescribing information and explicitly states the risk of TD, the importance of short-term use, and the need for immediate discontinuation if signs or symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, despite these warnings, many patients were prescribed Reglan for extended periods, sometimes exceeding 12 weeks, without adequate monitoring or informed consent about TD risk. This discrepancy between labeling and real-world prescribing practices has been a focus of litigation. Settlement-related considerations for affected patients in Illinois involve the statute of limitations, which governs the time frame within which a lawsuit must be filed. In Illinois, the statute of limitations for personal injury claims, including those related to drug-induced TD, is generally two years from the date the injury was discovered or should have been discovered through reasonable diligence. For TD, the timeline between exposure to Reglan and documented harm can be variable. Some patients develop symptoms after months of use, while others may not experience noticeable movements until years later. The FDA labeling indicates that risk increases with duration of treatment and cumulative dosage, but TD can also occur after shorter exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This variability complicates the determination of when the statute of limitations begins to run, as the 'discovery' date may be when a patient first notices abnormal movements, when a physician diagnoses TD, or when the patient becomes aware of the link between Reglan and their symptoms. Patients considering settlement should be aware that the FDA boxed warning serves as evidence that the manufacturer was aware of the TD risk and had a duty to warn prescribers and patients. The warning explicitly states that Reglan can cause TD and that the drug should be used for the shortest duration (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If a patient was prescribed Reglan for longer than 12 weeks without appropriate monitoring or was not informed of the TD risk, this may support a claim of inadequate warning. However, each case depends on individual circumstances, including the duration of use, the presence of symptoms, and the timing of diagnosis. In summary, Reglan carries a clear FDA boxed warning about TD risk, with specific guidance on limiting treatment duration and monitoring. The statute of limitations in Illinois for TD claims is generally two years from discovery of the injury. Patients who developed TD after Reglan use should consult with a legal professional to evaluate their specific timeline and potential claims.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan tardive dyskinesia claims in Illinois?

In Illinois, the statute of limitations for personal injury claims, including those related to Reglan-induced tardive dyskinesia, is generally two years from the date the injury was discovered or should have been discovered through reasonable diligence. Because TD symptoms can appear months or years after Reglan use, the discovery date may vary. It is crucial to consult with a legal professional to determine the applicable deadline for your specific case.

Does the FDA boxed warning for Reglan affect settlement claims?

Yes, the FDA boxed warning explicitly states that Reglan can cause tardive dyskinesia and that the drug should be used for the shortest duration necessary (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This warning serves as evidence that the manufacturer was aware of the risk and had a duty to warn prescribers and patients. If you were prescribed Reglan for longer than 12 weeks without adequate monitoring or informed consent, it may support a claim of inadequate warning.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Label for Reglan (metoclopramide)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.